Key terms
About STOK
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest STOK news
Apr 03
1:45am ET
Strong Buy Rating for Stoke Therapeutics’ STK-001 Backed by Positive KOL Feedback and Revolutionary Potential in Dravet Syndrome Treatment
Apr 01
3:45am ET
Stoke Stock (NASDAQ:STOK) Soars 73% on Drug Update; Is There More Upside Left?
Mar 28
5:32pm ET
Stoke Therapeutics Launches Public Offering for Clinical Development
Mar 28
10:59am ET
Biotech Alert: Searches spiking for these stocks today
Mar 28
6:43am ET
Stoke Therapeutics 5.556M share Secondary priced at $13.50
Mar 26
4:08pm ET
Stoke Therapeutics announces $75M common stock offering
Mar 26
8:15am ET
Wedbush Sticks to Their Buy Rating for Stoke Therapeutics (STOK)
Mar 26
6:30am ET
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Elevance Health (ELV) and Stoke Therapeutics (STOK)
Mar 26
6:18am ET
Stoke Therapeutics (STOK) was upgraded to a Buy Rating at TD Cowen
Mar 26
6:15am ET
Buy Rating Affirmed for Stoke Therapeutics’ STK-001 on Strong Clinical Data and Regulatory Support
Mar 26
5:55am ET
Stoke Therapeutics’ STK-001 Shows Promising Results: A Strong Buy Rating with Increased Price Target
Mar 25
4:02pm ET
Stoke Therapeutics reports Q4 EPS (60c), consensus (63c)
Mar 25
4:02pm ET
Stoke Therapeutics announces new data from STK-001 studies
Feb 16
11:22am ET
Biotech Alert: Searches spiking for these stocks today
Feb 16
5:37am ET
Stoke Therapeutics: Strong Buy on Promising Dravet Syndrome Treatment Data and Undervalued Market Position
Feb 07
8:34am ET
Buy Rating for Stoke Therapeutics: Anticipating STK-001’s Breakthrough in Dravet Syndrome Treatment
Jan 24
8:07am ET
Soleno Therapeutics announces appointments to its leadership team
Jan 10
7:16am ET
Buy Rating Affirmed for Stoke Therapeutics Amid Promising Drug Developments and Market Potential
Jan 07
5:45am ET
Stoke Therapeutics (STOK) Receives a Buy from BTIG
No recent press releases are available for STOK
STOK Financials
Key terms
Ad Feedback
STOK Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
STOK Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
